Menu
The Glaser laboratory in located in the Hadassah Medical Center and includes a basic research component studying pancreatic beta cell biology and how islet cell dysfunction contributes to the pathogenesis of Type 2 Diabetes. In addition, the laboratory collaborates with the Dor laboratory in the Hebrew University Medical School, providing clinical support for the development of novel plasma biomarkers for a wide spectrum of diseases.
In depth analysis of body fluids such as blood, urine and saliva can be leveraged to inform on physiologic and pathologic processes ongoing in the whole organism. Measurements of electrolytes and secreted proteins have been used for decades for this purpose, providing valuable but limited diagnostic insight. Our working hypothesis is that the diagnostic information derived from these fluids can be greatly enhanced by incorporating DNA, RNA, metabolomic and proteomic derived biomarkers. The clinical impact of such a multiomic biomarker set will be invaluable for early detection of disease, disease progression and analysis of treatment efficacy. In addition, it is expected to provide critical patient-specific disease characterization that can inform personalized therapeutic interventions.
My group will facilitate recruitment of patients, define optimal patient target populations and define and collect in depth clinical data that will then be leveraged to enhance the specificity and sensitivity of the multiomic biomarkers developed by others in the consortium.
Copyright 2023 LIQUIDBXÂ – All Rights Reserved
Produced by Webzilla